EPISODE · May 2, 2018 · 5 MIN
Recently Approved Drugs: Blinatumomab for B-cell precursor ALL
from ASCO Education
Alex Ganetsky, PharmD, BCOP, oncology clinical pharmacy specialist at the Hospital of the University of Pennsylvania in Philadelphia discusses the approval to blinatumomab (Blincyto, Amgen Inc.) for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.
Embed this episode
NOW PLAYING
Recently Approved Drugs: Blinatumomab for B-cell precursor ALL
0:00
5:05
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of ASCO Education?
This episode is 5 minutes long.
When was this ASCO Education episode published?
This episode was published on May 2, 2018.
Can I download this ASCO Education episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!